O²,O³,O⁴-Triacetyl-D-ribose | 85230-84-8

• 英文名称: O²,O³,O⁴-Triacetyl-D-ribose
• 英文别名: [(2R,3R,4R)-3,4-diacetyloxy-1-hydroxy-5-oxopentan-2-yl] acetate
• CAS: 85230-84-8
• 化学式: C₁₁H₁₆O₈
• 分子量: 276.243
• InChiKey: DIFVWABJLWGNOH-AXFHLTTASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  19
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  116
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  O²,O³,O⁴-Triacetyl-D-ribose 生成 N-acetyl-N-(4-chloro-benzenesulfonyl)-N'-(tri-O-acetyl-ξ-D-ribopyranosyl)-hydrazine
  参考文献：
  名称：

  Zinner et al., Justus Liebigs Annalen der Chemie, 1959, vol. 622, p. 133,147

  摘要：

  DOI：
• 作为产物：
  描述：

  O²,O³,O⁴-triacetyl-D-ribose-phenylimine 在 乙醇 、 溶剂黄146 作用下， 生成 O²,O³,O⁴-Triacetyl-D-ribose
  参考文献：
  名称：

  芳胺N-糖苷；水解芳胺-N-戊糖苷并制备结晶D-核糖。

  摘要：

  DOI：

  10.1021/jo01171a013

文献信息

• ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPUETIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME
  申请人：Benhida Rachid

  公开号：US20140179626A1

  公开（公告）日：2014-06-26

  Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.

  本文描述了作为药物的Acadesine衍生物，以及用于治疗癌症，特别是慢性髓细胞白血病的衍生物。此外，还描述了包含衍生物和至少一种第二活性成分的产品，作为联合产品进行同时、分离或顺序给药，用于治疗癌症，以及含有衍生物和药用可接受载体的制药组合物。最后，描述了抑制体外细胞增殖的方法，包括将体外细胞与衍生物接触，以及合成所述衍生物的方法。
• [EN] A PROCESS FOR THE PREPARATION OF N4-HYDROXYCYTIDINE AND ITS DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE N4-HYDROXYCYTIDINE ET DE SES DÉRIVÉS
  申请人：COUNCIL SCIENT IND RES

  公开号：WO2022234598A1

  公开（公告）日：2022-11-10

  This invention provides a process for the preparation of orthogonally protected ribose derivative. Which are further used as donor for the synthesis of N4-hydroxy cytidine and its derivatives by using commercially available materials under very mild reaction condition and short period of time. Thereafter N-hydroxylation of cytidine can be achieved in a short period of time. The intermediates or the final compounds thus obtained can be used for the treatment of viral infections.

  该发明提供了一种制备正交保护核糖衍生物的方法。在非常温和的反应条件和短时间内，使用商业上可获得的材料作为供体，进一步用于合成N4-羟基胞苷及其衍生物。然后，胞苷的N-羟基化可以在短时间内完成。因此，所得到的中间体或最终化合物可用于治疗病毒感染。
• Ellipticine derivative and production process thereof
  申请人：SUNTORY LIMITED

  公开号：EP0173462A2

  公开（公告）日：1986-03-05

  An ellipticine derivative having the general formula: wherein R represents a hydrogen atom, a hydroxyl group, an alkoxyl group having 1 to 4 carbon atoms, or an acyloxy group having 2 to 7 carbon atoms; R2 represents an aldose residue, a deoxyaldose residue, an N-acylaminoaldose residue having a substituted acyl group with 2 to 4 carbon atoms bonded to the N atom, an aldohexuronic amide residue, and aldohexuronic acid residue, an acylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated N-acylaminoaldose residue having an amino group substituted with an acyl group with 2 to 4carbon atoms and having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an acylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 2 to 4 carbon atoms or an arylacyl group with 7 to 9 carbon atoms, an arylalkylated aldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated deoxyaldose residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an alkylacyl group with 7 to 8 carbon atoms, an arylalkylated N-acylaminoaldose residue having an amino group with an acyl group with 2 to 4 carbon atoms and having, substituted for the hydrogen of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic amide residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms, an arylalkylated aldohexuronic acid ester residue having, substituted for the hydrogen atom of the hydroxyl group of the sugar, an arylalkyl group with 7 to 8 carbon atoms; and R3 represents a hydrogen atom, a linear, branched, cyclic, or cyclic-linear alkyl group having 1 to 5 carbon atoms; X0 represents a pharmaceutically acceptable inorganic or organic acid anion; and the bond represented by N⊕ - R2 in the general formula (I) represents a glycoside bond between a nitrogen atom in the 2-position of the ellipticine and a carbon atom in the 1-position of the sugar. These ellipticine derivatives have a strong antineoplastic or antitumor activity and, therefore, are expected to be effective as an antineoplastic or antitumor agent.

  一种具有通式的鞣花碱衍生物： 其中 R 代表氢原子、羟基、具有 1 至 4 个碳原子的烷氧基或具有 2 至 7 个碳原子的酰氧基； R2 代表醛糖残基、脱氧醛糖残基、N-酰氨基醛糖残基（其 N 原子上键有 2 至 4 个碳原子的取代酰基）、醛缩脲酰胺残基、醛缩脲酸残基、酰化醛糖残基（其糖羟基的氢原子被取代）、一种酰化脱醛糖残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化的 N-酰氨基醛糖残基，其氨基被 2 至 4 个碳原子的酰基取代，并具有 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代糖羟基的氢原子；酰化的醛缩酰胺残基，其具有一种酰化的醛缩己脲酰胺残基，其糖的羟基的氢原子被 2 至 4 个碳原子的烷酰基或 7 至 9 个碳原子的芳酰基取代、酰化醛缩醛酸酯残基，其糖羟基的氢原子被 2 至 4 个碳原子的烷基酰基或 7 至 9 个碳原子的芳基酰基取代、芳烷基化脱醛糖残基，其糖的羟基的氢原子被 7 至 8 个碳原子的烷酰基取代；芳烷基化 N-酰氨基醛糖残基，其氨基带有 2 至 4 个碳原子的酰基，并具有一种芳烷基化的醛缩脲酰胺残基，其氨基具有 2 至 4 个碳原子的酰基，并具有 7 至 8 个碳原子的芳烷基取代糖的羟基的氢原子、一种芳烷基化的醛缩脲酸酯残基，其糖的羟基的氢原子被具有 7 至 8 个碳原子的芳烷基取代；和 R3 代表氢原子、具有 1 至 5 个碳原子的直链、支链、环状或环状直链烷基； X0 代表药学上可接受的无机或有机酸阴离子；以及 通式（I）中 N⊕ - R2 所代表的键代表鞣花碱 2 位上的氮原子与糖 1 位上的碳原子之间的糖苷键。这些鞣花碱衍生物具有很强的抗肿瘤或抗肿瘤活性，因此有望成为有效的抗肿瘤或抗肿瘤药物。
• N6-substituted deoxyribose analogs of adenosines
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0181129A2

  公开（公告）日：1986-05-14

  There is disclosed a compound of the following general formula (I) or a pharmaceutically acceptable acid addition salt thereof, wherein R is cycloalkyl having from three to eleven ring members or R is one of the following groups of the formulae in which n is one, two, or three; X and Y are each, independently, H, lower alkyl, hydroxy, lower alkoxy, benzyloxy, nitro, amino or halogen; and Q is of the fomrula: in which Z is CH3, CH2Hal in which Hal stands for a halogen atom or CH2SCH3; and R2' or R3' are each, independently, H, lower alkyl, lower alkanoyl, benzoyl, benzoyl substituted by lower alkyl, lower alkoxy, or halogen or when taken together are lower alkylidene where the hydroxy groups are free or lower alkanoyl or benzoyl esters thereof. Also disclosed are processes for their manufacture, pharmaceutical compositions and methods for using said compounds and compositions. The compounds have highly desirable central nervous system and antihypertensive properties.

  本发明公开了一种通式如下的化合物（I） 或其药学上可接受的酸加成盐，其中 R 是具有三至十一个环成员的环烷基，或 R 是下式中的一个基团 其中 n 为 1、2 或 3；X 和 Y 各自独立地为 H、低级烷基、羟基、低级烷氧基、苄氧基、硝基、氨基或卤素；Q 为下式的基团： 其中 Z是CH3、CH2Hal（其中Hal代表卤素原子）或CH2S ；R2'或R3'各自独立地是H、低级烷基、低级烷酰基、苯甲酰基、被低级烷基、低级烷氧基或卤素取代的苯甲酰基，或者当它们组合在一起时是羟基游离的低级亚烷基或低级烷酰基或苯甲酰基酯。 此外，还公开了其制造工艺、药物组合物以及使用上述化合物和组合物的方法。 这些化合物具有非常理想的中枢神经系统和抗高血压特性。
• 4'-Demethylepipodophyllotoxin glycosides
  申请人：Bristol-Myers Squibb Company

  公开号：EP0455159A1

  公开（公告）日：1991-11-06

  The present invention relates to antitumor 4'-demethylepipodophyllotoxin glycosides having the formula wherein R is a pentose selected from the group consisting of β-D-ribopyranosyl, peracyl β-D-ribopyranosyl, β-D-xylopyranosyl, peracyl β-D-xylopyranosyl, α-D-xylopyranosyl, peracyl α-D-xylopyranosyl, α-D-arabinopyranosyl, 3,4-O-(C₁₋₄)alkylidene-D-ribopyranosyl, 2-O-acyl-3,4-O-(C₁₋₄)alkylidene-D-ribopyranosyl, and β-D-ribofuranosyl; P is hydrogen, or -PO₃H₂ or a pharmaceutically acceptable salt thereof.

  本发明涉及抗肿瘤的 4'-demethylepipodophyllotoxin苷，其式为 其中 R 是选自以下组别的戊糖 β-D-ribopyranosyl, peracyl β-D-ribopyranosyl、 β-D-吡喃木糖基、过酰基 β-D-吡喃木糖基、过酰基 β-D-吡喃木糖基、 α-D-xylopyranosyl, peracyl α-D-xylopyranosyl、 α-D-阿拉伯吡喃糖基、 3,4-O-(C₁₋₄)亚烷基-D-吡喃核糖、 2-O-酰基-3,4-O-(C₁₋₄)亚烷基-D-吡喃核糖基和 β-D-呋喃核糖基；P 是氢、或 -PO₃H₂ 或其药学上可接受的盐。